November 2, 2026

The Manager- Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update

This is pursuant to Regulation 30(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our communication dated July 30, 2026, in connection with the notice received on July 29, 2026 ('Notice') issued by the National Pharmaceutical Pricing Authority ('NPPA') for alleged overcharging under the Drugs (Prices Control) Order, 2013 ('DPCO, 2013') in relation to Symbicort Turbuhaler 160/4.5 (Inhaler).

We hereby inform that, the Hon'ble High Court of Delhi, vide its order dated October 29, 2026 ('Order'), has directed that no coercive steps be taken by NPPA in this matter, until the next date of hearing, listed on January 11, 2027.

Further, please find the details as required under the SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – A.

Kindly take the above information on record.

Thanking You,

For AstraZeneca Pharma India Limited

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.11.02 11:38:25 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer
ACS No.: A25784

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the authority	Hon'ble High Court of Delhi
2.	Nature and details of the action(s)	Order directing NPPA that no coercive steps be taken by NPPA in this matter, until the next date of hearing i.e. January 11, 2027
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	October 30, 2026
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Further to a show cause notice dated September 11, 2025, the Company had received the abovementioned Notice from NPPA and a subsequent reminder, alleging overcharging in connection with Symbicort Turbuhaler 160/4.5 (Inhaler) for the period from May 2016 to November 2025 under DPCO, 2013. The Company challenged the demand before the Hon'ble High Court of Delhi. Vide its Order, the Hon'ble High Court has directed that no coercive steps be taken by NPPA till the next date of hearing i.e. listed on January 11, 2027.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Order directs that NPPA cannot take coercive steps till the next hearing date, to recover Rs. 151,19,66,035/- approximately, comprised of alleged overcharged amount and interest upto 30th October, 2026.

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628